Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GREAT-2
2022-502494-41-00Phase 2Completed
- Sponsor
- NHS Tayside
- Start
- Sep 2023
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in bronchiectasis and Pseudomonal infection comparing Gremubamab with Placebo (2 arms). Started Sep 2023; status: completed.
02
Drugs
gremubamab
03
Conditions
bronchiectasisPseudomonal infection
Beyond the preview
Go deeper on 2022-502494-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502494-41-00.